Robert E. Waltermire - 12 Dec 2023 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Reporting relationship: Senior VP, Chief Pharma Dev.
Issuer ticker: MDGL
Reported as of: 12 Dec 2023
Net transaction value: -$512,604
SEC form: 4
Accepted by SEC: 14 Dec 2023, 16:30:08 UTC
Prior SEC filing: 02 Mar 2023
Next SEC filing: 18 Dec 2023
Source filing: View source filing
Reporting owner signature: /s/ Brian J. Lynch*

Key filing fact

Robert E. Waltermire filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 14 Dec 2023.

Key facts

This page summarizes Robert E. Waltermire's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
8 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 14 Dec 2023, 16:30.

Change

Previous filing in this sequence was filed on 02 Mar 2023.
Current net transaction value: -$512,604.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDGL transaction

Common Stock

Options Exercise

Transaction value: $114,296
Shares: +1,300
Change %: +23%
Price: $87.92
Shares after: 6,967
Date: 12 Dec 2023
Ownership: Direct
Footnotes: F1

MDGL transaction

Common Stock

Sale

Transaction value: $108,000
Shares: -500
Change %: -7.2%
Price: $216.00
Shares after: 6,467
Date: 12 Dec 2023
Ownership: Direct

MDGL transaction

Common Stock

Sale

Transaction value: $175,200
Shares: -800
Change %: -12%
Price: $219.00
Shares after: 5,667
Date: 12 Dec 2023
Ownership: Direct

MDGL transaction

Common Stock

Options Exercise

Transaction value: $219,800
Shares: +2,500
Change %: +44%
Price: $87.92
Shares after: 8,167
Date: 13 Dec 2023
Ownership: Direct
Footnotes: F1

MDGL transaction

Common Stock

Sale

Transaction value: $337,500
Shares: -1,500
Change %: -18%
Price: $225.00
Shares after: 6,667
Date: 13 Dec 2023
Ownership: Direct

MDGL transaction

Common Stock

Sale

Transaction value: $226,000
Shares: -1,000
Change %: -15%
Price: $226.00
Shares after: 5,667
Date: 13 Dec 2023
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MDGL transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -1,300
Change %: -5.2%
Price: $0.000000
Shares after: 23,700
Date: 12 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,300
Exercise price: $87.92
Footnotes: F1

MDGL transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -2,500
Change %: -11%
Price: $0.000000
Shares after: 21,200
Date: 13 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,500
Exercise price: $87.92
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

All shares issued pursuant to the exercise of the options reported herein represent 3,800 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

SEC remarks

*As attorney-in-fact for Reporting Person